Print Page |
RSS Feeds |
Email Alerts |
IR Contacts
Corporate Profile

SPNC develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are available in over 65 countries and are used to treat arterial blockages in the heart and legs and in the removal of pacemaker and defibrillator leads.

The Company’s Vascular Intervention (VI) products include a range of laser catheters for ablation of blockages in arteries above and below the knee, the AngioSculpt® scoring balloon used in both peripheral and coronary procedures, and the Stellarex™ drug coated balloon peripheral angioplasty platform, which received European CE mark approval in December 2014. The Company also markets support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions. The Company markets aspiration and cardiac laser catheters to treat blockages in the heart.

The Lead Management (LM) product line includes excimer laser sheaths, dilator sheaths, mechanical sheaths and accessories for the removal of pacemaker and defibrillator cardiac leads.

Investor EventsMore >>
Download Documentation J.P. Morgan Presentation
Download Documentation SPNC TCT Presentation
Get help downloading or viewing the above file types
Annual Reports
Download Documentation 2016 Annual Report
Download Documentation 2015 Annual Report
Stock Chart
SPNC (Common Stock)
Stock chart for: SPNC.O.  Currently trading at $38.45 with a 52 week high of $38.55 and a 52 week low of $19.80.
Stock Quote
SPNC (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%)0.00 (0.00%)
Data as of 08/09/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report

Download Documentation 2016 Annual Report
Recent NewsMore >>
08/10/17Spectranetics Announces Fundamental Change, Make-Whole Adjustment Event, Share Exchange Event and Supplemental Indenture for 2.625% Convertible Senior Notes due 2034Printer Friendly Version
08/03/17Spectranetics Reports Second Quarter 2017 Revenue of $74.7 millionPrinter Friendly Version
07/26/17Spectranetics Announces FDA Approval of Stellarex™ Drug-Coated BalloonPrinter Friendly Version
07/13/17Spectranetics Announces Second Quarter Earnings Release DatePrinter Friendly Version
Notice of Fundamental Change, Make-Whole Adjustment Event and Share Exchange Event and Supplemental IndentureClick here to download >>
SEC FilingsMore >>
Filing DateDescription
08/22/1715-12G     Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/22/1715-12G     Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/14/17Report of unscheduled material events or corporate event Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
08/11/17Statement of changes in beneficial ownership of securities Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
Receive Email AlertsE-mail Alert Icon
Sign up to receive email alerts whenever Spectranetics posts new information to the site. Just enter your email address and click Submit.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources